IL193625A - History 10– (3 – Hydroxyphenyl) - 3a, 10,9,4 – Tetrahydro – 9,2, 10a– Triaza – Cyclopenta [b] Fluorene – 3,1 – Dione, Pharmaceutical preparations containing them and their use in the preparation of a drug for the treatment of responding diseases For inhibition of quinazine eg5 - Google Patents
History 10– (3 – Hydroxyphenyl) - 3a, 10,9,4 – Tetrahydro – 9,2, 10a– Triaza – Cyclopenta [b] Fluorene – 3,1 – Dione, Pharmaceutical preparations containing them and their use in the preparation of a drug for the treatment of responding diseases For inhibition of quinazine eg5Info
- Publication number
- IL193625A IL193625A IL193625A IL19362508A IL193625A IL 193625 A IL193625 A IL 193625A IL 193625 A IL193625 A IL 193625A IL 19362508 A IL19362508 A IL 19362508A IL 193625 A IL193625 A IL 193625A
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- hydroxy
- triaza
- dione
- tetrahydro
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 6
- 201000010099 disease Diseases 0.000 title description 4
- 239000003814 drug Substances 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 title description 3
- 230000005764 inhibitory process Effects 0.000 title description 2
- QVPYRRVDVZHTOY-UHFFFAOYSA-N 10-(3-hydroxyphenyl)-8,11,13-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2,4,6-tetraene-12,14-dione Chemical class OC=1C=C(C=CC=1)C1N2C(CC=3C4=CC=CC=C4NC1=3)C(NC2=O)=O QVPYRRVDVZHTOY-UHFFFAOYSA-N 0.000 title 1
- 102000010638 Kinesin Human genes 0.000 title 1
- 108010063296 Kinesin Proteins 0.000 title 1
- KKBNYCNHSBKGPP-UHFFFAOYSA-N fluorene-1,3-dione Chemical compound C1=CC=C2C3=CC(=O)CC(=O)C3=CC2=C1 KKBNYCNHSBKGPP-UHFFFAOYSA-N 0.000 description 255
- -1 S-oxo-thiomorpholin-4-yl Chemical group 0.000 description 62
- 239000001257 hydrogen Substances 0.000 description 56
- 229910052739 hydrogen Inorganic materials 0.000 description 56
- 150000002431 hydrogen Chemical class 0.000 description 49
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 37
- 150000001875 compounds Chemical class 0.000 description 30
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 29
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 25
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 20
- 150000003839 salts Chemical class 0.000 description 20
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 18
- 229910052736 halogen Inorganic materials 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 13
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 13
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 12
- 229910052731 fluorine Inorganic materials 0.000 description 12
- 239000011737 fluorine Substances 0.000 description 12
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 11
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 11
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 229910052801 chlorine Inorganic materials 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 125000004433 nitrogen atom Chemical group N* 0.000 description 9
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 8
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 description 7
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 7
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 7
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 7
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 230000009826 neoplastic cell growth Effects 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 description 4
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 3
- SDOFDUOEOQMORM-UHFFFAOYSA-N 3a,4,9,10-tetrahydroimidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1C2=CC=CC=C2C2=C1CN1C(=O)NC(=O)C1C2 SDOFDUOEOQMORM-UHFFFAOYSA-N 0.000 description 3
- YLALAGRHKZLHFM-UHFFFAOYSA-N C1(NC(C2N1C=C1N=C3C=CC=CC3C1C2)=O)=O Chemical compound C1(NC(C2N1C=C1N=C3C=CC=CC3C1C2)=O)=O YLALAGRHKZLHFM-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000004523 tetrazol-1-yl group Chemical group N1(N=NN=C1)* 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ZGNLFUXWZJGETL-YUSKDDKASA-N (Z)-[(2S)-2-amino-2-carboxyethyl]-hydroxyimino-oxidoazanium Chemical compound N[C@@H](C\[N+]([O-])=N\O)C(O)=O ZGNLFUXWZJGETL-YUSKDDKASA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 108010006654 Bleomycin Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- MLFKVJCWGUZWNV-UHFFFAOYSA-N L-alanosine Natural products OC(=O)C(N)CN(O)N=O MLFKVJCWGUZWNV-UHFFFAOYSA-N 0.000 description 2
- 229940124613 TLR 7/8 agonist Drugs 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229950005033 alanosine Drugs 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 229960001561 bleomycin Drugs 0.000 description 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960000435 oblimersen Drugs 0.000 description 2
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 2
- 229950003600 ombrabulin Drugs 0.000 description 2
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 239000004066 vascular targeting agent Substances 0.000 description 2
- QUBIQSPIOYKQPT-BVAGGSTKSA-N (3as,10r)-10-(3-hydroxyphenyl)-2-(2-imidazol-1-ylethyl)-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C=C3C=2C[C@@]1(C)C1=O)OC)C=2C=C(O)C=CC=2)C(=O)N1CCN1C=CN=C1 QUBIQSPIOYKQPT-BVAGGSTKSA-N 0.000 description 1
- WAMCIKZGULRFLR-NAKRPHOHSA-N (3as,10r)-10-(3-hydroxyphenyl)-2-[3-(isobutylamino)propyl]-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C=C4C=3C[C@@]3(C)C(=O)N(CCCNCC(C)C)C(=O)N32)OC)=CC=CC(O)=C1 WAMCIKZGULRFLR-NAKRPHOHSA-N 0.000 description 1
- ZKMGOJKWLLAXHT-QPPBQGQZSA-N (3as,10r)-10-(3-hydroxyphenyl)-6-(2-methoxyethoxy)-2,3a-dimethyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C=C4C=3C[C@@]3(C)C(=O)N(C)C(=O)N32)OCCOC)=CC=CC(O)=C1 ZKMGOJKWLLAXHT-QPPBQGQZSA-N 0.000 description 1
- YFPJATJOSUOKFK-SQHAQQRYSA-N (3as,10r)-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-2-(2-pyrrolidinoethyl)-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C=C3C=2C[C@@]1(C)C1=O)OC)C=2C=C(O)C=CC=2)C(=O)N1CCN1CCCC1 YFPJATJOSUOKFK-SQHAQQRYSA-N 0.000 description 1
- IRRMCNDODRIEDY-UHSQPCAPSA-N (3as,10r)-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-2-(3-piperidinopropyl)-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C=C3C=2C[C@@]1(C)C1=O)OC)C=2C=C(O)C=CC=2)C(=O)N1CCCN1CCCCC1 IRRMCNDODRIEDY-UHSQPCAPSA-N 0.000 description 1
- UFAWAQWMTBPORY-SQHAQQRYSA-N (3as,10r)-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-2-[2-[(2-methylpyrazol-3-yl)amino]ethyl]-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C=C3C=2C[C@@]1(C)C1=O)OC)C=2C=C(O)C=CC=2)C(=O)N1CCNC1=CC=NN1C UFAWAQWMTBPORY-SQHAQQRYSA-N 0.000 description 1
- NAYBOGLOOBPEHD-UHSQPCAPSA-N (3as,10r)-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-2-[3-(4-methylpiperazino)propyl]-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C=C3C=2C[C@@]1(C)C1=O)OC)C=2C=C(O)C=CC=2)C(=O)N1CCCN1CCN(C)CC1 NAYBOGLOOBPEHD-UHSQPCAPSA-N 0.000 description 1
- YEBWROCSRIACOF-OFNKIYASSA-N (3as,10r)-2-(2-aminoethyl)-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C=C4C=3C[C@@]3(C)C(=O)N(CCN)C(=O)N32)OC)=CC=CC(O)=C1 YEBWROCSRIACOF-OFNKIYASSA-N 0.000 description 1
- BETGTFJRGSAYNF-OFNKIYASSA-N (3as,10r)-2-(2-bromoethyl)-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C=C4C=3C[C@@]3(C)C(=O)N(CCBr)C(=O)N32)OC)=CC=CC(O)=C1 BETGTFJRGSAYNF-OFNKIYASSA-N 0.000 description 1
- NJNFODDYMHUHBX-OFNKIYASSA-N (3as,10r)-2-(2-bromoethyl)-5-fluoro-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C(=C4C=3C[C@@]3(C)C(=O)N(CCBr)C(=O)N32)F)OC)=CC=CC(O)=C1 NJNFODDYMHUHBX-OFNKIYASSA-N 0.000 description 1
- MJHMZKQXRLVEMZ-KNQAVFIVSA-N (3as,10r)-2-(2-bromoethyl)-6-chloro-7-fluoro-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C3=C(C4=CC(Cl)=C(F)C=C4N3)C[C@@]3(N2C(=O)N(CCBr)C3=O)C)=CC=CC(O)=C1 MJHMZKQXRLVEMZ-KNQAVFIVSA-N 0.000 description 1
- HCZJDYFVQMFEOQ-QPPBQGQZSA-N (3as,10r)-2-(3-chloropropyl)-5-fluoro-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C(=C4C=3C[C@@]3(C)C(=O)N(CCCCl)C(=O)N32)F)OC)=CC=CC(O)=C1 HCZJDYFVQMFEOQ-QPPBQGQZSA-N 0.000 description 1
- KEKLLZIXMZMZSX-NAKRPHOHSA-N (3as,10r)-2-[2-(4-acetylpiperazino)ethyl]-6-chloro-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1CN(C(=O)C)CCN1CCN1C(=O)[C@]2(C)CC(C3=CC(Cl)=CC=C3N3)=C3[C@@H](C=3C=C(O)C=CC=3)N2C1=O KEKLLZIXMZMZSX-NAKRPHOHSA-N 0.000 description 1
- WYTODKJVWAQSIY-IRPSRAIASA-N (3as,10r)-2-[2-(azepan-1-yl)ethyl]-6-(difluoromethoxy)-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(OC(F)F)=CC=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCN1CCCCCC1 WYTODKJVWAQSIY-IRPSRAIASA-N 0.000 description 1
- QZSOHXNZULFLOD-NAKRPHOHSA-N (3as,10r)-2-[2-(azepan-1-yl)ethyl]-6-bromo-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(Br)=CC=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCN1CCCCCC1 QZSOHXNZULFLOD-NAKRPHOHSA-N 0.000 description 1
- DYQOSGVDEYXUDS-NAKRPHOHSA-N (3as,10r)-2-[2-(azepan-1-yl)ethyl]-6-chloro-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(Cl)=CC=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCN1CCCCCC1 DYQOSGVDEYXUDS-NAKRPHOHSA-N 0.000 description 1
- BOIMNLWPSMZXNH-NAKRPHOHSA-N (3as,10r)-2-[2-(cyclobutylamino)ethyl]-6-ethoxy-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C=C3C=2C[C@@]1(C)C1=O)OCC)C=2C=C(O)C=CC=2)C(=O)N1CCNC1CCC1 BOIMNLWPSMZXNH-NAKRPHOHSA-N 0.000 description 1
- PAJZGMJKSCGYBT-SQHAQQRYSA-N (3as,10r)-2-[2-(diethylamino)ethyl]-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(OC)=CC=C4NC=32)=O)CCN(CC)CC)=CC=CC(O)=C1 PAJZGMJKSCGYBT-SQHAQQRYSA-N 0.000 description 1
- IJOGJYQFQUBNTK-KCWPFWIISA-N (3as,10r)-2-[2-(tert-butylamino)ethyl]-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C=C4C=3C[C@@]3(C)C(=O)N(CCNC(C)(C)C)C(=O)N32)OC)=CC=CC(O)=C1 IJOGJYQFQUBNTK-KCWPFWIISA-N 0.000 description 1
- KYDUYOHHRSDOPH-MVSFAKPFSA-N (3as,10r)-2-[3-(4-acetylpiperazino)propyl]-6-ethoxy-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C=C3C=2C[C@@]1(C)C1=O)OCC)C=2C=C(O)C=CC=2)C(=O)N1CCCN1CCN(C(C)=O)CC1 KYDUYOHHRSDOPH-MVSFAKPFSA-N 0.000 description 1
- HUDFWSLIANLHNC-VIZCGCQYSA-N (3as,10r)-2-[3-(azepan-1-yl)propyl]-6-(difluoromethoxy)-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(OC(F)F)=CC=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCCN1CCCCCC1 HUDFWSLIANLHNC-VIZCGCQYSA-N 0.000 description 1
- HVPBGOFVVURROZ-UHSQPCAPSA-N (3as,10r)-2-[3-(azepan-1-yl)propyl]-6-bromo-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(Br)=CC=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCCN1CCCCCC1 HVPBGOFVVURROZ-UHSQPCAPSA-N 0.000 description 1
- OEQFGGKFTVPWHZ-UHSQPCAPSA-N (3as,10r)-2-[3-(azepan-1-yl)propyl]-6-chloro-7-fluoro-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(Cl)=C(F)C=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCCN1CCCCCC1 OEQFGGKFTVPWHZ-UHSQPCAPSA-N 0.000 description 1
- UBJBIVJDKXHSPT-NAKRPHOHSA-N (3as,10r)-2-[3-(cyclobutylamino)propyl]-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C=C3C=2C[C@@]1(C)C1=O)OC)C=2C=C(O)C=CC=2)C(=O)N1CCCNC1CCC1 UBJBIVJDKXHSPT-NAKRPHOHSA-N 0.000 description 1
- VGDRNXIKGWMAKX-KCWPFWIISA-N (3as,10r)-2-[3-(tert-butylamino)propyl]-6-chloro-7-fluoro-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(Cl)=C(F)C=C4NC=32)=O)CCCNC(C)(C)C)=CC=CC(O)=C1 VGDRNXIKGWMAKX-KCWPFWIISA-N 0.000 description 1
- KCYAAWSGFWNWME-NAKRPHOHSA-N (3as,10r)-2-[3-[ethyl(2-hydroxyethyl)amino]propyl]-5-fluoro-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=C(F)C(OC)=CC=C4NC=32)=O)CCCN(CCO)CC)=CC=CC(O)=C1 KCYAAWSGFWNWME-NAKRPHOHSA-N 0.000 description 1
- CWMMLEIQGPHVAB-BVAGGSTKSA-N (3as,10r)-5-fluoro-10-(3-hydroxyphenyl)-2-[2-(isopropylamino)ethyl]-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C(=C4C=3C[C@@]3(C)C(=O)N(CCNC(C)C)C(=O)N32)F)OC)=CC=CC(O)=C1 CWMMLEIQGPHVAB-BVAGGSTKSA-N 0.000 description 1
- UAOMCCOBNMTUBC-SQHAQQRYSA-N (3as,10r)-5-fluoro-10-(3-hydroxyphenyl)-2-[2-[isopropyl(methyl)amino]ethyl]-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C(=C4C=3C[C@@]3(C)C(=O)N(CCN(C)C(C)C)C(=O)N32)F)OC)=CC=CC(O)=C1 UAOMCCOBNMTUBC-SQHAQQRYSA-N 0.000 description 1
- WMMSVXZBOBLARK-UHSQPCAPSA-N (3as,10r)-5-fluoro-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-2-(3-piperidinopropyl)-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C(=C3C=2C[C@@]1(C)C1=O)F)OC)C=2C=C(O)C=CC=2)C(=O)N1CCCN1CCCCC1 WMMSVXZBOBLARK-UHSQPCAPSA-N 0.000 description 1
- PHCMNNWBEBNKSN-SQHAQQRYSA-N (3as,10r)-5-fluoro-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-2-[2-(3-pyrrolin-1-yl)ethyl]-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C(=C3C=2C[C@@]1(C)C1=O)F)OC)C=2C=C(O)C=CC=2)C(=O)N1CCN1CC=CC1 PHCMNNWBEBNKSN-SQHAQQRYSA-N 0.000 description 1
- DWBHKARRRYWMBU-UHSQPCAPSA-N (3as,10r)-5-fluoro-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-2-[2-(4-methylpiperidino)ethyl]-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C=2NC3=CC=C(C(=C3C=2C[C@@]1(C)C1=O)F)OC)C=2C=C(O)C=CC=2)C(=O)N1CCN1CCC(C)CC1 DWBHKARRRYWMBU-UHSQPCAPSA-N 0.000 description 1
- QDPPYVKHJJISLY-SQHAQQRYSA-N (3as,10r)-5-fluoro-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-2-[2-[methyl(propargyl)amino]ethyl]-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C(=C4C=3C[C@@]3(C)C(=O)N(CCN(C)CC#C)C(=O)N32)F)OC)=CC=CC(O)=C1 QDPPYVKHJJISLY-SQHAQQRYSA-N 0.000 description 1
- BWNMBYLAGWZSIZ-BWKNWUBXSA-N (3as,10r)-6-(difluoromethoxy)-2-[2-(2-hydroxyethylamino)ethyl]-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C3=C(C4=CC(OC(F)F)=CC=C4N3)C[C@@]3(N2C(=O)N(CCNCCO)C3=O)C)=CC=CC(O)=C1 BWNMBYLAGWZSIZ-BWKNWUBXSA-N 0.000 description 1
- KXSVATBWEYDBNC-BWKNWUBXSA-N (3as,10r)-6-(difluoromethoxy)-2-[2-(ethylamino)ethyl]-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(OC(F)F)=CC=C4NC=32)=O)CCNCC)=CC=CC(O)=C1 KXSVATBWEYDBNC-BWKNWUBXSA-N 0.000 description 1
- CYPAGNONAHVZMV-BVAGGSTKSA-N (3as,10r)-6-bromo-10-(3-hydroxyphenyl)-2-[2-(isobutylamino)ethyl]-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(Br)=CC=C4NC=32)=O)CCNCC(C)C)=CC=CC(O)=C1 CYPAGNONAHVZMV-BVAGGSTKSA-N 0.000 description 1
- HQZGHWIVHKATLT-OFNKIYASSA-N (3as,10r)-6-bromo-2-(3-chloropropyl)-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C3=C(C4=CC(Br)=CC=C4N3)C[C@@]3(N2C(=O)N(CCCCl)C3=O)C)=CC=CC(O)=C1 HQZGHWIVHKATLT-OFNKIYASSA-N 0.000 description 1
- PMAIBJVFUCHGDY-BVAGGSTKSA-N (3as,10r)-6-bromo-2-[2-(cyclopropylmethylamino)ethyl]-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(Br)=CC=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCNCC1CC1 PMAIBJVFUCHGDY-BVAGGSTKSA-N 0.000 description 1
- UQLNNGXHOHIRIV-RDGATRHJSA-N (3as,10r)-6-chloro-10-(3-hydroxyphenyl)-2-[2-(isopropylamino)ethyl]-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(Cl)=CC=C4NC=32)=O)CCNC(C)C)=CC=CC(O)=C1 UQLNNGXHOHIRIV-RDGATRHJSA-N 0.000 description 1
- MKBCYGOOBTZDIA-SQHAQQRYSA-N (3as,10r)-6-chloro-10-(3-hydroxyphenyl)-2-[3-(isobutylamino)propyl]-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(Cl)=CC=C4NC=32)=O)CCCNCC(C)C)=CC=CC(O)=C1 MKBCYGOOBTZDIA-SQHAQQRYSA-N 0.000 description 1
- DTWQLDWXCSVPIT-BVAGGSTKSA-N (3as,10r)-6-chloro-10-(3-hydroxyphenyl)-2-[3-(isopropylamino)propyl]-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(Cl)=CC=C4NC=32)=O)CCCNC(C)C)=CC=CC(O)=C1 DTWQLDWXCSVPIT-BVAGGSTKSA-N 0.000 description 1
- PVMBYXWXEUUCEC-BVAGGSTKSA-N (3as,10r)-6-chloro-10-(3-hydroxyphenyl)-3a-methyl-2-(2-pyrrolidinoethyl)-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(Cl)=CC=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCN1CCCC1 PVMBYXWXEUUCEC-BVAGGSTKSA-N 0.000 description 1
- YADIYVXAEYUNML-OFNKIYASSA-N (3as,10r)-6-chloro-2-(3-chloropropyl)-7-fluoro-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C3=C(C4=CC(Cl)=C(F)C=C4N3)C[C@@]3(N2C(=O)N(CCCCl)C3=O)C)=CC=CC(O)=C1 YADIYVXAEYUNML-OFNKIYASSA-N 0.000 description 1
- KPQDFMMLCZQPPN-RDGATRHJSA-N (3as,10r)-6-chloro-2-[2-(cyclopropylamino)ethyl]-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(Cl)=CC=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCNC1CC1 KPQDFMMLCZQPPN-RDGATRHJSA-N 0.000 description 1
- GJYXQWLMTWRQKW-BVAGGSTKSA-N (3as,10r)-6-chloro-2-[2-(diethylamino)ethyl]-7-fluoro-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(Cl)=C(F)C=C4NC=32)=O)CCN(CC)CC)=CC=CC(O)=C1 GJYXQWLMTWRQKW-BVAGGSTKSA-N 0.000 description 1
- SWJLHPVVTGKKGA-SQHAQQRYSA-N (3as,10r)-6-chloro-2-[3-(cyclopropylmethylamino)propyl]-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(Cl)=CC=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCCNCC1CC1 SWJLHPVVTGKKGA-SQHAQQRYSA-N 0.000 description 1
- LRFBDNVVJQMEHJ-BVAGGSTKSA-N (3as,10r)-6-chloro-2-[3-[ethyl(methyl)amino]propyl]-7-fluoro-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(Cl)=C(F)C=C4NC=32)=O)CCCN(C)CC)=CC=CC(O)=C1 LRFBDNVVJQMEHJ-BVAGGSTKSA-N 0.000 description 1
- QRARJNXTUCCMRI-SQHAQQRYSA-N (3as,10r)-6-chloro-7-fluoro-10-(3-hydroxyphenyl)-3a-methyl-2-[3-(3-pyrrolin-1-yl)propyl]-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound N1([C@@H](C2=C(C3=CC(Cl)=C(F)C=C3N2)C[C@]1(C1=O)C)C=2C=C(O)C=CC=2)C(=O)N1CCCN1CC=CC1 QRARJNXTUCCMRI-SQHAQQRYSA-N 0.000 description 1
- AWWVUFSHKNSCME-QPPBQGQZSA-N (3as,10r)-6-chloro-7-fluoro-10-(3-hydroxyphenyl)-3a-methyl-2-[3-(methylamino)propyl]-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(Cl)=C(F)C=C4NC=32)=O)CCCNC)=CC=CC(O)=C1 AWWVUFSHKNSCME-QPPBQGQZSA-N 0.000 description 1
- ZWMJRKXUNHTOQD-OFNKIYASSA-N (3as,10r)-6-ethoxy-10-(3-hydroxyphenyl)-2,3a-dimethyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@@H]2C=3NC4=CC=C(C=C4C=3C[C@@]3(C)C(=O)N(C)C(=O)N32)OCC)=CC=CC(O)=C1 ZWMJRKXUNHTOQD-OFNKIYASSA-N 0.000 description 1
- MZSXOQKNNNKQOJ-SQHAQQRYSA-N (3as,10r)-6-ethoxy-2-[3-(ethylamino)propyl]-10-(3-hydroxyphenyl)-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3C(=O)N(C([C@]3(C)CC=3C4=CC(OCC)=CC=C4NC=32)=O)CCCNCC)=CC=CC(O)=C1 MZSXOQKNNNKQOJ-SQHAQQRYSA-N 0.000 description 1
- SJDOZOAQUMUCDK-NAKRPHOHSA-N (3as,10r)-7-fluoro-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-2-(2-piperidinoethyl)-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3[C@@](C(N(CCN4CCCCC4)C3=O)=O)(C)CC=3C=4C=C(C(=CC=4NC=32)F)OC)=CC=CC(O)=C1 SJDOZOAQUMUCDK-NAKRPHOHSA-N 0.000 description 1
- QFRAEWCXUDPJRT-SQHAQQRYSA-N (3as,10r)-7-fluoro-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-2-[2-[methyl(propargyl)amino]ethyl]-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3[C@@](C(N(CCN(C)CC#C)C3=O)=O)(C)CC=3C=4C=C(C(=CC=4NC=32)F)OC)=CC=CC(O)=C1 QFRAEWCXUDPJRT-SQHAQQRYSA-N 0.000 description 1
- OIFXAHCUTZXKQD-RDGATRHJSA-N (3as,10r)-7-fluoro-2-[2-(2-hydroxyethylamino)ethyl]-10-(3-hydroxyphenyl)-6-methoxy-3a-methyl-9,10-dihydro-4h-imidazo[1,5-b]$b-carboline-1,3-quinone Chemical compound C1([C@H]2N3[C@@](C(N(CCNCCO)C3=O)=O)(C)CC=3C=4C=C(C(=CC=4NC=32)F)OC)=CC=CC(O)=C1 OIFXAHCUTZXKQD-RDGATRHJSA-N 0.000 description 1
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 1
- NVKGVBZZSJFQLM-UHFFFAOYSA-N 1-(2-chloroethyl)-1-nitrosourea Chemical compound NC(=O)N(N=O)CCCl NVKGVBZZSJFQLM-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- TZYVRXZQAWPIAB-FCLHUMLKSA-N 5-amino-3-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-4h-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1SC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O TZYVRXZQAWPIAB-FCLHUMLKSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- GYAMLRWKZITQHS-UHFFFAOYSA-N CC12N(CC=3NC4=CC=CC=C4C3C1)C(NC2=O)=O Chemical compound CC12N(CC=3NC4=CC=CC=C4C3C1)C(NC2=O)=O GYAMLRWKZITQHS-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- LKJPYSCBVHEWIU-UHFFFAOYSA-N N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide Chemical compound C=1C=C(C#N)C(C(F)(F)F)=CC=1NC(=O)C(O)(C)CS(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- AUYLVPGDOVEOML-UHFFFAOYSA-N [6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]-[4-(piperidin-1-ylmethoxy)phenyl]methanone Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 AUYLVPGDOVEOML-UHFFFAOYSA-N 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229940097647 casodex Drugs 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- QKSGNWJOQMSBEP-UHFFFAOYSA-N diethyl-[[6-[[4-(hydroxycarbamoyl)phenyl]carbamoyloxymethyl]naphthalen-2-yl]methyl]azanium;chloride Chemical compound [Cl-].C1=CC2=CC(C[NH+](CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 QKSGNWJOQMSBEP-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229950003954 isatoribine Drugs 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229950002884 lexatumumab Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229950001869 mapatumumab Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
- 229960000639 pazopanib Drugs 0.000 description 1
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- JHDKZFFAIZKUCU-ZRDIBKRKSA-N pracinostat Chemical compound ONC(=O)/C=C/C1=CC=C2N(CCN(CC)CC)C(CCCC)=NC2=C1 JHDKZFFAIZKUCU-ZRDIBKRKSA-N 0.000 description 1
- YSQDQEOIFWWVHA-UHFFFAOYSA-A promune Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].CC1=C(C(=O)NC(N)=C)N=CN1C1OC(COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)OC2C(OC(C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)OC2C(OC(C2)N2C(NC(=O)C(C)=C2)=O)CO)C(OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)O)C1 YSQDQEOIFWWVHA-UHFFFAOYSA-A 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 229950010550 resiquimod Drugs 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 190014017285 satraplatin Chemical compound 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229950000578 vatalanib Drugs 0.000 description 1
- YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 1
- LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06110295 | 2006-02-22 | ||
| EP06119038 | 2006-08-16 | ||
| PCT/EP2007/051688 WO2007096393A1 (en) | 2006-02-22 | 2007-02-21 | Indolopyridines as eg5 kinesin modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL193625A0 IL193625A0 (en) | 2009-05-04 |
| IL193625A true IL193625A (en) | 2015-01-29 |
Family
ID=37964159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL193625A IL193625A (en) | 2006-02-22 | 2008-08-21 | History 10– (3 – Hydroxyphenyl) - 3a, 10,9,4 – Tetrahydro – 9,2, 10a– Triaza – Cyclopenta [b] Fluorene – 3,1 – Dione, Pharmaceutical preparations containing them and their use in the preparation of a drug for the treatment of responding diseases For inhibition of quinazine eg5 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8530493B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP1996592B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5349056B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101415354B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101389628B (cg-RX-API-DMAC7.html) |
| AR (1) | AR059609A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007217560B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0708233A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2643488C (cg-RX-API-DMAC7.html) |
| EA (1) | EA015150B1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1205510A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL193625A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2008010801A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ571357A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI377207B (cg-RX-API-DMAC7.html) |
| UA (1) | UA96592C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007096393A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200808070B (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| US20050192356A1 (en) * | 2004-02-27 | 2005-09-01 | Babish John G. | Synergistic anti-inflammatory pharmaceutical compositions and methods of use |
| US7838524B2 (en) | 2004-04-30 | 2010-11-23 | Bayer Healthcare Llc | Substituted pyrazolyl urea derivatives useful in the treatment of cancer |
| DE602005024572D1 (de) | 2004-08-18 | 2010-12-16 | 4Sc Ag | Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin |
| NZ589276A (en) | 2005-02-03 | 2012-06-29 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors and erlotinib (tarceva) |
| SI1901729T1 (sl) * | 2005-05-13 | 2012-05-31 | Topotarget Uk Ltd | Farmacevtske formulacije HDAC inhibitorjev |
| CA2627923C (en) * | 2005-11-10 | 2016-01-12 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer |
| EP2033962A1 (en) * | 2007-08-22 | 2009-03-11 | 4Sc Ag | Tetracyclic indolopyridines as EG5 inhibitors |
| CN101868446A (zh) * | 2007-09-25 | 2010-10-20 | 托波塔吉特英国有限公司 | 某些异羟肟酸化合物的合成方法 |
| EP2098524A1 (en) * | 2008-03-05 | 2009-09-09 | 4Sc Ag | Process for preparing enantiomerically pure indolopyrinidines |
| SI2262493T1 (sl) * | 2008-03-07 | 2015-07-31 | Onxeo Dk Branch Of Onxeo S.A. France | Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| CN109467555A (zh) * | 2018-06-21 | 2019-03-15 | 广东蓝堡生物科技有限公司 | 一种他达那非衍生物及其制备方法和应用 |
| CN109160914B (zh) * | 2018-11-17 | 2020-06-16 | 重庆文理学院 | 一种双吲哚并吡啶类衍生物的合成方法及在抗肿瘤中的应用 |
| CN111529526B (zh) * | 2020-04-14 | 2021-04-23 | 广州领晟医疗科技有限公司 | 一种化合物在制备治疗急性胰腺炎的药物中的用途 |
| CN113577063B (zh) * | 2021-08-30 | 2022-08-16 | 广州领晟医疗科技有限公司 | 一种化合物在制备治疗炎性肠病的药物中的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0357122A3 (en) | 1988-08-29 | 1991-10-23 | Duphar International Research B.V | Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties |
| GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
| DE19744257B4 (de) | 1997-10-07 | 2004-04-15 | Zentaris Gmbh | Beta-Carboline und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen |
| US6890933B1 (en) | 2000-02-24 | 2005-05-10 | President And Fellows Of Harvard College | Kinesin inhibitors |
| AU2002213421A1 (en) | 2000-10-03 | 2002-04-15 | Lilly Icos Llc | Condensed pyridoindole derivatives |
| WO2002095361A2 (en) | 2001-05-22 | 2002-11-28 | President And Fellows Of Harvard College | Identification of anti-protozoal agents |
| CA2460939C (en) | 2001-09-19 | 2008-07-29 | Pharmacia Corporation | Substituted pyrazolyl compounds for the treatment of inflammation |
| EP2292615A1 (en) | 2002-02-01 | 2011-03-09 | AstraZeneca AB | Quinazoline compounds |
| AU2003247891A1 (en) | 2002-07-08 | 2004-01-23 | Merck & Co., Inc. | Mitotic kinesin binding site |
| US7022850B2 (en) | 2003-05-22 | 2006-04-04 | Bristol-Myers Squibb Co. | Bicyclicpyrimidones and their use to treat diseases |
| JP4580932B2 (ja) | 2003-06-12 | 2010-11-17 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害剤のプロドラッグ |
| CN1960725A (zh) | 2004-03-15 | 2007-05-09 | Ptc医疗公司 | 用于抑制血管发生的四环咔啉衍生物 |
| DE602005024572D1 (de) * | 2004-08-18 | 2010-12-16 | 4Sc Ag | Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin |
| AU2006212863A1 (en) | 2005-02-10 | 2006-08-17 | Merck Sharp & Dohme Corp. | Mitotic kinesin inhibitors |
| WO2007144384A1 (en) | 2006-06-14 | 2007-12-21 | 4Sc Ag | Pyrazolopyrimidones |
| WO2008006883A2 (en) | 2006-07-13 | 2008-01-17 | 4Sc Ag | Benzopyranopyrazoles |
-
2007
- 2007-02-21 US US12/280,424 patent/US8530493B2/en not_active Expired - Fee Related
- 2007-02-21 EA EA200801739A patent/EA015150B1/ru not_active IP Right Cessation
- 2007-02-21 CN CN2007800065292A patent/CN101389628B/zh not_active Expired - Fee Related
- 2007-02-21 EP EP07704690.2A patent/EP1996592B1/en not_active Withdrawn - After Issue
- 2007-02-21 WO PCT/EP2007/051688 patent/WO2007096393A1/en not_active Ceased
- 2007-02-21 EP EP14180089.6A patent/EP2824105B1/en not_active Withdrawn - After Issue
- 2007-02-21 AU AU2007217560A patent/AU2007217560B2/en not_active Ceased
- 2007-02-21 JP JP2008555789A patent/JP5349056B2/ja not_active Expired - Fee Related
- 2007-02-21 UA UAA200811328A patent/UA96592C2/uk unknown
- 2007-02-21 KR KR1020087020411A patent/KR101415354B1/ko not_active Expired - Fee Related
- 2007-02-21 CA CA2643488A patent/CA2643488C/en active Active
- 2007-02-21 BR BRPI0708233-9A patent/BRPI0708233A2/pt not_active IP Right Cessation
- 2007-02-21 EP EP21165375.3A patent/EP3862354A1/en not_active Withdrawn
- 2007-02-21 NZ NZ571357A patent/NZ571357A/xx not_active IP Right Cessation
- 2007-02-21 MX MX2008010801A patent/MX2008010801A/es active IP Right Grant
- 2007-02-22 AR ARP070100750A patent/AR059609A1/es unknown
- 2007-02-26 TW TW096106590A patent/TWI377207B/zh not_active IP Right Cessation
-
2008
- 2008-08-21 IL IL193625A patent/IL193625A/en active IP Right Grant
- 2008-09-19 ZA ZA2008/08070A patent/ZA200808070B/en unknown
-
2015
- 2015-06-25 HK HK15106078.5A patent/HK1205510A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200815441A (en) | 2008-04-01 |
| EP1996592B1 (en) | 2014-08-27 |
| HK1205510A1 (en) | 2015-12-18 |
| EP2824105B1 (en) | 2021-03-31 |
| EA200801739A1 (ru) | 2009-04-28 |
| IL193625A0 (en) | 2009-05-04 |
| US20090233902A1 (en) | 2009-09-17 |
| CN101389628A (zh) | 2009-03-18 |
| CA2643488A1 (en) | 2007-08-30 |
| NZ571357A (en) | 2010-11-26 |
| AU2007217560A1 (en) | 2007-08-30 |
| AR059609A1 (es) | 2008-04-16 |
| UA96592C2 (uk) | 2011-11-25 |
| BRPI0708233A2 (pt) | 2011-05-24 |
| KR101415354B1 (ko) | 2014-07-04 |
| MX2008010801A (es) | 2008-09-05 |
| CN101389628B (zh) | 2013-02-27 |
| US8530493B2 (en) | 2013-09-10 |
| EA015150B1 (ru) | 2011-06-30 |
| EP1996592A1 (en) | 2008-12-03 |
| CA2643488C (en) | 2014-08-05 |
| ZA200808070B (en) | 2014-03-26 |
| JP5349056B2 (ja) | 2013-11-20 |
| EP2824105A1 (en) | 2015-01-14 |
| KR20080098043A (ko) | 2008-11-06 |
| AU2007217560B2 (en) | 2012-06-28 |
| TWI377207B (en) | 2012-11-21 |
| JP2009527533A (ja) | 2009-07-30 |
| WO2007096393A1 (en) | 2007-08-30 |
| EP3862354A1 (en) | 2021-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113980032B (zh) | 稠合四环类衍生物、其制备方法及其在医药上的应用 | |
| WO2023072297A1 (zh) | 含氮的四环化合物、其制备方法及其在医药上的应用 | |
| CN117203207A (zh) | 桥环类化合物、其制备方法及其在医药上的应用 | |
| AU2007217560B2 (en) | Indolopyridines as Eg5 kinesin modulators | |
| TW202322819A (zh) | 含氮的四環化合物、其製備方法及其在醫藥上的應用 | |
| JP2009527533A5 (cg-RX-API-DMAC7.html) | ||
| AU2007205962B2 (en) | Spiro compounds and methods of use | |
| HU229875B1 (en) | Tricyclic inhibitors of poly(adp-ribose) polymerases | |
| WO2008153207A1 (ja) | ビシクロアニリン誘導体 | |
| CN109311876A (zh) | 杂芳基雌激素受体调节剂及其用途 | |
| TW201041875A (en) | JAK kinase modulating compounds and methods of use thereof | |
| CN112457310A (zh) | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 | |
| CN111909173A (zh) | 苯并氧氮杂*噁唑烷酮化合物及其使用方法 | |
| JPWO2005026126A1 (ja) | Crf拮抗剤および二環式複素環化合物 | |
| EP1994033A1 (en) | Indolopyridines as eg5 kinesin modulators | |
| IE904141A1 (en) | 5,11-DIHYDRO-6H-DIPYRIDO[3,2-b:2',3'-e][1,4]DIAZEPINES AND¹THEIR USE IN THE PREVENTION OR TREATMENT OF HIV INFECTION | |
| CN120365289A (zh) | 稠环类化合物、其制备方法及其在医药上的应用 | |
| EP1682123A1 (en) | Cancer treatment method | |
| KR20240167844A (ko) | 질소 함유 헤테로시클릭 화합물, 이의 제조 방법 및 이의 의학적 응용 | |
| WO2009024613A1 (en) | Tetracyclic indolopyridines as eg5 inhibitors | |
| AU2024319888A1 (en) | Heteroaryl compound, preparation method therefor, and use thereof in medicine | |
| CN117903172A (zh) | 取代的含氮杂芳基类化合物、其制备方法及其在医药上的应用 | |
| CN114656486B (zh) | 嘌呤酮类化合物、其制备方法及其在医药上的应用 | |
| CN114053276A (zh) | 一种parp抑制剂tsl-1502中间体tsl-1502m的用途 | |
| CA3300208A1 (en) | Heteroaryl compound, preparation method therefor, and use thereof in medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |